Gender
Item
male or female
boolean
C0079399 (UMLS CUI [1])
Age
Item
age 18-65 years
boolean
C0001779 (UMLS CUI [1])
Schizophrenia Subtype Any | Schizoaffective Disorder Subtype Any | Schizophreniform Disorder
Item
diagnosis of schizophrenia, any subtype, schizoaffective disorder, any subtype or schizophreniform disorder
boolean
C0036341 (UMLS CUI [1,1])
C0449560 (UMLS CUI [1,2])
C1552551 (UMLS CUI [1,3])
C0036337 (UMLS CUI [2,1])
C0449560 (UMLS CUI [2,2])
C1552551 (UMLS CUI [2,3])
C0036358 (UMLS CUI [3])
Outpatients Pharmaceutical Preparations Compliance
Item
well established compliance with out-patient medications
boolean
C0029921 (UMLS CUI [1,1])
C0013227 (UMLS CUI [1,2])
C3714738 (UMLS CUI [1,3])
Clozapine
Item
current treatment with clozapine for a minimum of one year
boolean
C0009079 (UMLS CUI [1])
Insulin Resistance Evidence of | Impaired fasting glucose | Glucose measurement | Hyperinsulinism | fasting insulin level | Homeostasis model assessment Insulin Resistance | Insulin Sensitivity Index
Item
evidence of insulin resistance: impaired fasting glucose (glucose ≥100 mg/dl) or hyperinsulinemia (fasting insulin ≥ 15 ng/dl) or a homa-ir (homeostasis model assessment for insulin resistance) (fasting glucose x fasting insulin/22.5) ≥2 or a si (insulin sensitivity index)
boolean
C0021655 (UMLS CUI [1,1])
C0332120 (UMLS CUI [1,2])
C1272092 (UMLS CUI [2])
C0337438 (UMLS CUI [3])
C0020459 (UMLS CUI [4])
C2016107 (UMLS CUI [5])
C1829779 (UMLS CUI [6,1])
C0021655 (UMLS CUI [6,2])
C0920563 (UMLS CUI [7,1])
C0918012 (UMLS CUI [7,2])
Informed Consent Unable
Item
inability to provide informed consent
boolean
C0021430 (UMLS CUI [1,1])
C1299582 (UMLS CUI [1,2])
Substance Use Disorders
Item
current substance abuse
boolean
C0038586 (UMLS CUI [1])
Illness Significant | Congestive heart failure | Cardiovascular Disease Severe | Kidney Diseases | Creatinine measurement, serum | Anemia | Hemoglobin measurement | Psychiatric Unstable
Item
significant medical illness, including congestive heart failure, severe cardiovascular disease, renal disease (serum creatinine > 1.5), anemia (hemoglobin < 11.0 gm/dl) or psychiatrically unstable
boolean
C0221423 (UMLS CUI [1,1])
C0750502 (UMLS CUI [1,2])
C0018802 (UMLS CUI [2])
C0007222 (UMLS CUI [3,1])
C0205082 (UMLS CUI [3,2])
C0022658 (UMLS CUI [4])
C0201976 (UMLS CUI [5])
C0002871 (UMLS CUI [6])
C0518015 (UMLS CUI [7])
C0205487 (UMLS CUI [8,1])
C0443343 (UMLS CUI [8,2])
Hepatic impairment Severe | Liver diseases | Serum transaminase increased | Alanine aminotransferase measurement | Study Subject Participation Status
Item
severe hepatic impairment, active liver disease or increased serum transaminase levels (alt>2.0x upper limit of normal) if at any time, alt increases to 2x uln, the subject's participation in the study will be terminated.
boolean
C0948807 (UMLS CUI [1,1])
C0205082 (UMLS CUI [1,2])
C0023895 (UMLS CUI [2])
C0859350 (UMLS CUI [3])
C0201836 (UMLS CUI [4])
C2348568 (UMLS CUI [5])
Pregnancy | Breast Feeding | Childbearing Potential Contraceptive methods Unable | Childbearing Potential Contraceptive methods Unwilling
Item
women of child bearing potential who are pregnant, breastfeeding, or who are unwilling or unable to use an effective form of birth control during the entire study
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
C3831118 (UMLS CUI [3,1])
C0700589 (UMLS CUI [3,2])
C1299582 (UMLS CUI [3,3])
C3831118 (UMLS CUI [4,1])
C0700589 (UMLS CUI [4,2])
C0558080 (UMLS CUI [4,3])
Weight-Loss Agents
Item
treatment with agents that induce weight loss
boolean
C0376606 (UMLS CUI [1])
Diabetes Mellitus | Thyroid Diseases
Item
history of diabetes mellitus or thyroid disease
boolean
C0011849 (UMLS CUI [1])
C0040128 (UMLS CUI [2])
Oral hypoglycemic | Insulin
Item
current treatment with an oral hypoglycemic agent or insulin
boolean
C0359086 (UMLS CUI [1])
C0021641 (UMLS CUI [2])
Hypersensitivity rosiglitazone | Hypersensitivity rosiglitazone Component
Item
known hypersensitivity to rosiglitazone or any of its components
boolean
C0020517 (UMLS CUI [1,1])
C0289313 (UMLS CUI [1,2])
C0020517 (UMLS CUI [2,1])
C0289313 (UMLS CUI [2,2])
C1705248 (UMLS CUI [2,3])
Glucose measurement, fasting | Atypical antipsychotic Impairing Glucose metabolism | olanzapine | Pharmaceutical Preparations conventional Potency low | Thioridazine | Chlorpromazine
Item
fasting glucose >126 mg/dl11. treatment with other atypical antipsychotic agents thought to impair glucose metabolism (olanzapine) or low potency conventional agents (thioridazine, chlorpromazine)
boolean
C0202045 (UMLS CUI [1])
C1276996 (UMLS CUI [2,1])
C0221099 (UMLS CUI [2,2])
C0596620 (UMLS CUI [2,3])
C0171023 (UMLS CUI [3])
C0013227 (UMLS CUI [4,1])
C0439858 (UMLS CUI [4,2])
C0678792 (UMLS CUI [4,3])
C0205251 (UMLS CUI [4,4])
C0039943 (UMLS CUI [5])
C0008286 (UMLS CUI [6])